Yulanka Castro Dominguez, MD
Interventional Cardiology · Ashland, OHNPI 1629404223
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Boston Scientific at 57.2% of the total. Reporting peaked in 2024 at $34,940 and has fallen 90.4% since, to $3,348 in 2025.
Across 257 payments — averaging $276.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$41K
- Medtronic$25K
- Regeneron$2K
- Inari Medical, Inc.$1K
- Abbott$849
- W. L. Gore & Associates, Inc.$311
- plus $1K from 22 others
Across 2 payments — averaging $14,400 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- W. L. Gore & Associates, Inc.$29K
What the payments were for
- Consulting fees$7,07910%
- Speaking & faculty fees$41,58158%
- Travel & lodging$11,21716%
- Food & beverage$11,23516%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 43 | $40,677 |
| Medtronic(2 entities) | 129 | $24,699 |
| Regeneron | 2 | $1,954 |
| Inari Medical, Inc. | 12 | $1,368 |
| Abbott | 22 | $849 |
| W. L. Gore & Associates, Inc. | 3 | $311 |
| Novartis | 9 | $171 |
| Philips North America LLC | 2 | $138 |
| Stryker | 2 | $135 |
| Penumbra, Inc. | 1 | $103 |
| Amgen | 5 | $98 |
| Inquis Medical, Inc. | 1 | $61 |
| Atricure, Inc. | 3 | $60 |
| Abiomed | 2 | $60 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $51 |
| Impulse Dynamics (USA) Inc. | 1 | $45 |
| Pfizer | 3 | $45 |
| Terumo Medical Corporation | 1 | $38 |
| Merck | 2 | $34 |
| Scpharmaceuticals Inc. | 2 | $32 |
| Novo Nordisk | 2 | $31 |
| Cordis US CORP. | 1 | $31 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $30 |
| Shockwave Medical, Inc | 1 | $24 |
| Surmodics, Inc. | 1 | $18 |
| Siemens Medical Solutions USA, Inc. | 1 | $18 |
| Chiesi USA, Inc. | 1 | $17 |
| Cardiva Medical, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EKOSONIC$29,825
- HawkOne$10,143
- RESOLUTE ONYX$5,615
- ONYX FRONTIER$3,753
- FLOWTRIEVER CATHETER, S$999
- CT THROMBECTOMY SYSTEM KIT$999
- TurboHawk$850
- IN.PACT Admiral$663
- Venous Wolf$338
- JETi All In One Non-Sterile Kit$280
- Resolute$209
- GORE VIABAHN Endoprosthesis$190
- VIVA XT CRT-D$188
- JETI$145
- ESPRIT$141
- GENERAL VASCULAR INTERVENTION$132
- US Und$118
- Indigo System$103
- GENERAL VASCULAR ACCESS$103
How this compares
$71,112 in reported general payments places this provider in the 85th percentile of 256 interventional cardiology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 71 | $106,734 |
| XareltoRivaroxaban | 63 | $79,784 |
| BrilintaTicagrelor | 19 | $13,946 |
| Atorvastatin Calcium | 138 | $1,843 |
| Cilostazol | 76 | $1,736 |
| ClopidogrelClopidogrel Bisulfate | 94 | $1,139 |
| Rosuvastatin Calcium | 77 | $1,010 |
| Ezetimibe | 35 | $878 |
| Losartan Potassium | 42 | $483 |
| Metoprolol Succinate | 35 | $478 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 34 | $449 |
| Amlodipine Besylate | 44 | $369 |
| Carvedilol | 17 | $324 |
| Nitroglycerin | 13 | $246 |
| Spironolactone | 18 | $192 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $45 | $106,73471 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 256 interventional cardiology providers in Ohio.
Other interventional cardiology in Ashland
- Gary AnselColumbus$3.3M
- John CheathamColumbus$1.4M
- Carlos Sanchez SotoColumbus$1.1M
- Steven YakubovColumbus$907K
- Timothy HenryCincinnati$605K
- Mitchell SilverColumbus$562K
- John PhillipsColumbus$410K
- John CorlCincinnati$390K
- Santiago GarciaCincinnati$360K
- Atish MathurMansfield$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.